{"page_content": "3\nESG R eport 2022\nOur vision to make the world a better place is foundational to Agios. We are driven to improve the lives of \nthose fighting life-threatening and life-altering genetically defined diseases, including those that have often \nbeen overlooked or neglected. We have pioneered two novel therapeutic approaches \u2014 IDH inhibition and \nPK activation \u2014 and continue to focus on creating an environment in which scientific innovation on behalf  \nof patients can thrive. \nOur ESG program is centered around our commitments to:\nPatients\n09     Case Study: Advancing Care for an \nUnderserved Patient Community\n10     Access to Medicines and  \nAffordable Pricing\n13     Safety of Clinical Trial Participants\n14    Drug Safety\n16     Case Study: Patient Voice  \nin Clinical Trials08 28 18 34 Employees\n19    Culture\n20     Employee Recruitment, \nEngagement, and Retention\n22     Diversity and Inclusion\n26     Health and Safety\n27     Case Study: Reimagining WorkOur Communities & World\n29     Case Study: Season of Service 2021\n30     Case Study: Increasing Diversity  \nin Life Sciences\n32     Community Involvement\n33     Energy and Greenhouse Gas \nEmissions\n33     Environmental Stewardship and \nCorporate ResponsibilityEthics & Values\n35     Oversight of Sustainable \nPractices\n36     Ethical Business Practices \nand Marketing\n37    Data Security and Privacy\n39    Corporate Governance\n41    Agios Awards\n42    Safe Harbor Statement\nESG Program  Objectives\n", "metadata": {"source": "NASDAQ_AGIO_2021.pdf", "page": 2, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}